Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance ("USOPTIVAL")
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,300
- 试验地点
- 16
- 主要终点
- Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing
研究概览
简要总结
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
详细描述
This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination.
Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 45 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must be 45-84 years of age.
- •Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery.
- •Able to comprehend, sign, and date the written informed consent document.
- •Must be 45-84 years of age.
- •Able and willing to undergo a standard-of-care screening colonoscopy within 60 days.
- •Able to comprehend, sign, and date the written informed consent document.
排除标准
- •Arm A Only:
- •1. Subject with curative biopsy during colonoscopy.
- •Arm B Only:
- •Subjects with positive FIT Test results in the 6 months preceding enrollment.
- •Subject has a current diagnosis of cancer.
- •Arms A & B:
- •Subject has a personal history of aerodigestive or digestive tract cancers.
- •Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer.
- •Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer:
- •Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
- •Familial adenomatous polyposis ("FAP", including attenuated FAP).
- •Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome").
- •Serrated polyposis syndrome
- •2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer.
- •One first-degree relative with CRC diagnosed before the age of
- •A significant disease which, in the Investigator's opinion, would exclude the subject from the study.
- •Legal incapacity or limited mental capacity.
- •Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent.
- •The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions.
- •The patient is known to be pregnant when recruited or during her participation in the study.
结局指标
主要结局
Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing
时间窗: Within 12 months of sample collection
Samples Collected for Testing
次要结局
未报告次要终点